Biotech and Pharmaceuticals Pharmaceuticals

  • Don't get so swept up in trying to predict where specific stocks are going that you ignore what they're saying about the market as a whole.

  • Futures pared gains Wednesday after the first look at first-quarter GDP showed the economy contracted at a sharper pace than expected.

  • How can a company that performed well during this recession be shunned by investors? Let Cramer explain.

  • flu_outbreak3.jpg

    Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.

  • Nasonex Ad

    I didn't have much of a weekend. I was putting out swine flu fires via work emails and dealing with a really bad allergy attack. Plus, it kinda gets cut short by having to go to bed so early (6 o'clock) in order to anchor "Worldwide Exchange" at 4 a.m. ET.

  • dendreon.jpg

    Next week's gonna be crazy, especially Tuesday aka "Dendreon Day." Shortly after I'm done anchoring "Worldwide Exchange" early Monday morning I'll be flying to Chicago to cover the highly anticipated data release on DNDN's Provenge. That's the name of the biotech company's unique, experimental treatment for prostate cancer.

  • pfizer_hq.jpg

    At Pfizer's annual shareholder meeting in Atlanta this morning, investors approved a version of "Say on Pay."

  • roche_logo.jpg

    It's a good thing I'm working the graveyard shift this month anchoring "Worldwide Exchange" at four o'clock in the morning. It was about the time that I woke up to go to work today at 1 a.m. ET that Roche and Genentech sent out their press releases announcing that their cancer drug Avastin didn't meet the main goal of a study to see if it extended the lives of people with early stage colon cancer.

  • Byetta Needle

    Shortly after Eli Lilly reported way better than expected earnings this morning, Amylin Pharmaceuticals fired a new salvo in its escalating proxy battle with billionaire activist investor Carl Icahn.

  • dendreon.jpg

    Not a surprise, but my post yesterday on what one reader called the analyst "flip-flop" on Dendreon generated a lot of responses and queries.

  • dendreon_logo_new.jpg

    As late as the day before the positive Dendreon data on its prostate cancer treatment Provenge came out, biotech analyst Jonathan Aschoff at Brean Murray Carret & Co. reiterated his "Sell" rating and $1 price target on the stock in a research note to clients. Today he's offering a bit of a mea culpa.

  • Investors are eager to hear results from Amylin and Biogen, Thursday. It seems the future of both firms could lie in the hands of Fast Money friend Carl Icahn!

  • The Dow advanced Wednesday, boosted by an encouraging "beige-book" report from the Federal Reserve, a better-than-expected manufacturing report from the New York Fed and as Procter & Gamble raised its dividend. Techs remained underwater as Intel's lack of guidance rattled the sector.

  • Stocks opened lower Wednesday as Intel's after-hours earnings report the day before dragged down tech stocks and a warning from Wal-Mart hit the broader indexes.

  • Twitter

    In my less than five weeks on Twitter, I've gotten ideas for four blogs and late yesterday, for the first time, I got a legit news tip off a tweet (for the uninitiated, that's what the short messages sent on Twitter are called.)

  • Stock futures indicated a mixed open Wednesday as Intel's after-hours earnings report the day before dragged down tech stocks.

  • Oh, the fun the late-night comics could have with this one. The makers of the little blue pill are a little red-faced on the Emerald Isle.

  • dendreon_logo_new2.jpg

    Dendreon is up yet again today on heavy volume. Several investors have emailed me and one analyst voicemailed me asking if I know what's going on. I don't. And I see no news.

  • Victory for vernakalant! No, that's not German. It's the scientific, generic name of the experimental heart rhythm maintenance drug at a little Canadian company called Cardiome. The announcement came out Wednesday evening that Merck is hooking up with CRME in yet another partnership deal between big pharma and baby biotech.

  • lilly_hq.jpg

    Drug names are a favorite topic of mine. So, can someone please explain why the proposed commercial name for Eli Lilly's new bloodthinner in the U.S. is "Effient" with two f's, but in the UK, where the pill is making its debut today, it's going by "Efient" with only one f?